Fundraising Fox

EpimAb Biotherapeutics

Shanghai, CN · 5 known investors

epimab.com ↗

EpimAb Biotherapeutics develops bispecific antibody drugs for immuno-oncology and other high-need therapeutic areas using its proprietary FIT-Ig platform, with a pipeline of clinical programs (EMB-01, EMB-06, EMB-07) and preclinical candidates. The company has an R&D center in Shanghai and pursues global licensing and co-development partnerships.

BiotechHealthtech

Investors · 5

Decheng CapitalMenlo Park
ShangBay Capital LLCPalo Alto
TCG LabsSan Francisco
3E Bioventures CapitalreportedPalo Alto
Sherpa Healthcare PartnersreportedGrand Cayman

In the news

Candid Therapeutics Raises $370M in Fundingfinsmes.com · Sep 2024Asher raises $55M; Roche's Huntington's trial; EpimAb bags $120Mdelveinsight.com · Mar 2021Chinese biopharma firm EpimAb bags $74m Series Bdealstreetasia.com · Jun 2019EpimAb Biotherapeutics Raises $74M in Series B Financing - BioSpacebiospace.com · Jun 2019EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies - BioSpacebiospace.com · Apr 2017

Frequently asked questions

What does EpimAb Biotherapeutics do?
EpimAb Biotherapeutics develops bispecific antibody drugs for immuno-oncology and other high-need therapeutic areas using its proprietary FIT-Ig platform, with a pipeline of clinical programs (EMB-01, EMB-06, EMB-07) and preclinical candidates. The company has an R&D center in Shanghai and pursues global licensing and co-development partnerships.
Who are EpimAb Biotherapeutics's investors?
EpimAb Biotherapeutics's investors include Decheng Capital, ShangBay Capital LLC, TCG Labs, 3E Bioventures Capital, Sherpa Healthcare Partners.
Where is EpimAb Biotherapeutics headquartered?
EpimAb Biotherapeutics is headquartered in Shanghai, CN.